Eiger Biopharmaceuticals (NASDAQ:EIGR) is scheduled to issue its quarterly earnings data after the market closes on Wednesday, March 21st. Analysts expect the company to announce earnings of ($1.02) per share for the quarter.
Eiger Biopharmaceuticals (NASDAQ:EIGR) last announced its earnings results on Monday, March 12th. The biotechnology company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.09). On average, analysts expect Eiger Biopharmaceuticals to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
Shares of Eiger Biopharmaceuticals (NASDAQ:EIGR) opened at $9.50 on Tuesday. Eiger Biopharmaceuticals has a one year low of $6.10 and a one year high of $16.20. The company has a current ratio of 5.85, a quick ratio of 5.85 and a debt-to-equity ratio of 0.58. The stock has a market cap of $96.85, a price-to-earnings ratio of -1.95 and a beta of 1.70.
EIGR has been the topic of several recent research reports. Oppenheimer set a $34.00 target price on shares of Eiger Biopharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, December 7th. Zacks Investment Research raised shares of Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a research note on Tuesday, January 9th. Ladenburg Thalmann Financial Services initiated coverage on shares of Eiger Biopharmaceuticals in a research note on Wednesday, January 3rd. They set a “buy” rating and a $32.00 target price on the stock. ValuEngine raised shares of Eiger Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $17.00 target price (down previously from $35.00) on shares of Eiger Biopharmaceuticals in a research note on Tuesday, January 16th. Two research analysts have rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $27.25.
TRADEMARK VIOLATION NOTICE: This story was originally published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.thelincolnianonline.com/2018/03/20/eiger-biopharmaceuticals-eigr-set-to-announce-quarterly-earnings-on-wednesday.html.
About Eiger Biopharmaceuticals
Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.